Who are Ganeden BC30's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Probiotic Vivomixx, Mesalazine plus Lactobacillus casei, Probiotic (Lactobacillus reuteri Prodentis, Combizym + Bifidobacteri, "Probiotics" and "Metronidazole", Lactobacillus Fermentum.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ganeden-bc30.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ganeden BC30 — Competitive Intelligence Brief

Ganeden BC30 (Ganeden BC30) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology.

marketed Probiotic Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ganeden BC30 (Ganeden BC30) — Massachusetts General Hospital. Ganeden BC30 is a probiotic strain of Bacillus coagulans that promotes gastrointestinal health by producing lactic acid and supporting beneficial gut microbiota.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Ganeden BC30 TARGET	Ganeden BC30	Massachusetts General Hospital	marketed	Probiotic
Probiotic Vivomixx	Probiotic Vivomixx	University of Milan	marketed	Probiotic
Mesalazine plus Lactobacillus casei	Mesalazine plus Lactobacillus casei	Hospital Cristo Re	marketed	Anti-inflammatory agent plus probiotic combination
Probiotic (Lactobacillus reuteri Prodentis	Probiotic (Lactobacillus reuteri Prodentis	Universidad de Colima	marketed	Probiotic
Combizym + Bifidobacteri	Combizym + Bifidobacteri	RenJi Hospital	marketed	Enzyme and probiotic combination
"Probiotics" and "Metronidazole"	"Probiotics" and "Metronidazole"	Peking University Shenzhen Hospital	marketed	Antibiotic + Probiotic combination
Lactobacillus Fermentum	Lactobacillus Fermentum	HEM Pharma Inc.	marketed	Live biotherapeutic / Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ganeden BC30 — Competitive Intelligence Brief. https://druglandscape.com/ci/ganeden-bc30. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab